Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications
March 05 2020 - 8:30AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that Heather Rowe Armstrong has joined the company as Vice
President of Investor Relations and Corporate Communications. In
this role, Ms. Armstrong will be responsible for communicating
Arcutis’ business objectives and accomplishments to all key
stakeholders, including shareholders, the global investment
community, media and employees.
“Heather is an exceptional investor relations
and corporate communications professional with a proven track
record of successfully developing and executing on strategic
investor relations and corporate communications programs,” said
John Smither, Chief Financial Officer of Arcutis. “Her breadth of
communications experience, particularly in the biopharmaceutical
industry and specifically in dermatology, makes her the ideal fit
for Arcutis, especially on the heels of our recent successful
IPO.”
Ms. Armstrong brings to Arcutis more than 16
years of strategic communications experience, with 13 years of
dedicated investor relations experience. Previously, Ms. Armstrong
was Vice President of Investor Relations and Corporate
Communications at Dynavax Technologies Corporation. Before that she
was Senior Director of Investor Relations and Corporate
Communications at Five Prime Therapeutics. Prior to that, she was
Director of Investor Relations at KYTHERA Biopharmaceuticals
(acquired by Allergan). She previously held various investor
relations and communications roles with increasing responsibility
at AeroVironment, Allos Therapeutics (acquired by Spectrum
Pharmaceuticals), Janus Capital Group and Myogen (acquired by
Gilead Sciences). Ms. Armstrong holds an M.A. in Mass
Communications/Public Relations from Texas Tech University and a
B.A. in Communication Studies, with minors in Marketing and
Journalism from New Mexico State University. She is an active
member of the National Investor Relations Institute (NIRI) and has
served on the board of directors of the NIRI Rocky Mountain Chapter
and the NIRI Los Angeles Chapter.
About Arcutis - Bioscience, applied to the
skin.
Arcutis is a late-stage biopharmaceutical
company focused on developing and commercializing treatments for
unmet needs in immune-mediated dermatological diseases and
conditions, or immuno-dermatology. Arcutis exploits recent
innovations in inflammation and immunology to develop potential
best-in-class therapies against validated biological targets,
leveraging our deep development, formulation and commercialization
expertise to bring to market novel dermatology treatments, while
maximizing our probability of technical success and financial
resources. Arcutis is currently developing three novel compounds
(topical roflumilast cream (ARQ-151), topical roflumilast foam
(ARQ-154) and ARQ-252) for multiple indications, including
psoriasis, atopic dermatitis, seborrheic dermatitis and eczema. For
more information, please visit www.arcutis.com or follow the
Company on LinkedIn.
Contact:John W. SmitherChief Financial
Officerjsmither@arcutis.com
Investors and Media:Heather Rowe ArmstrongVice
President, Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024